NK Cell Surface Marker Profile for Enhanced Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NK cell therapies face challenges in achieving high cytotoxic activity against target cells, such as K562 cells, and there is a lack of effective combinations with antibody drugs that utilize ADCC activity.
Innovation Solution
The development of NK cells with specific surface marker profiles, including CD16-positive, CD56-high, CD57-negative, NKG2C-positive, NKG2A-low or negative, and CD94-positive, which are cultured in media containing IL-2 or serum-free conditions to achieve cytotoxicity of 50% or higher when co-cultured with K562 cells at a 1:1 ratio. Additionally, a method involving the mixing of NK cells with antibodies before administration to enhance ADCC activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary NK cells are used as effecter cells, then CD16 expression is high, but cytotoxic activity against target cells is low (10-20%)
Solution Approach 1:
The patent changes the surface marker expression parameters of NK cells by selecting for CD56high CD16+ phenotype and culturing in IL-2 containing medium, transforming them from low cytotoxicity primary NK cells to high cytotoxicity effector cells with 50% or higher cytotoxic activity
Solution Approach 2:
The patent performs preliminary cultivation of NK cells in IL-2 containing medium before use as effecter cells, enabling them to develop high cytotoxic activity and appropriate surface marker expression profiles prior to actual target cell engagement
2Quantity of substance
If NK cells are cultivated to increase quantity, then sufficient amount for therapy is obtained, but cytotoxic activity may be diluted
Solution Approach 1:
The patent maintains high cytotoxic activity (50% or higher) while scaling up NK cell numbers through cultivation in IL-2 containing medium, achieving both sufficient quantity for therapy and high reliability of cytotoxic function
Solution Approach 2:
The patent ensures continuous high cytotoxic activity through prolonged cultivation in IL-2 containing medium, maintaining the effector cell phenotype and functional capability throughout the expansion process
3Reliability
If NK cells are combined with antibody drugs to enhance ADCC activity, then therapeutic efficacy is increased, but combination complexity increases
Solution Approach 1:
The patent pre-cultures and prepares NK cells with optimized surface marker expression (CD56high CD16+) before combining with antibody drugs, establishing the cellular component in advance to maximize ADCC activity when combined with the antibody therapy
Solution Approach 2:
The patent merges NK cell therapy with antibody drug therapy, combining the ADCC capability of NK cells with the targeted binding of antibodies to achieve synergistic therapeutic effects against tumor cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described NK cells exhibit significantly higher cytotoxic activity against target cells, with cytotoxicity rates of 50% or higher, and when combined with specific antibodies, they enhance ADCC activity, potentially reducing side reactions and increasing therapeutic efficacy.
Implementation Method 1
As one of the mechanisms of the cytotoxicity of NK cells, antibody-dependent cellular cytotoxicity (ADCC) is known. NK cells have Fc receptors (CD16) on the cell surfaces thereof, and ADCC is a mechanism that NK cells bind to antibodies binding with target cells via the Fc receptors to injure the target cells.
Implementation Method 2
the step of culturing the cells remained after the elimination of T cells in a medium containing 2500 to 2813 IU/mL of IL-2 as a sole cytokine
Data Source
AI summary
An NK cell showing higher cytotoxic activity is provided. An object of the present invention is to provide a pharmaceutical composition for NK cell therapies expected to be highly effective. The present invention provides an NK cell having the following characteristics of (1) and (2) or a population thereof: (1) the NK cell is CD16-positive, highly expresses CD56, and is CD57-negative, and (2) the NK cell is NKG2C-positive, is NKG2A-negative or lowly expresses NKG2A, and is CD94-positive. The present invention also provides a pharmaceutical composition containing a population of such NK cells, and a therapeutically effective amount of antibodies.